Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02399124 | Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma(ICE-SECRET) | active not recruiting | N/A | 120 | IceCure Medical Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY |
| 11 |
| Jan 6, 2026 |
| clinicaltrials |
| NCT05336266 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma(KetoROCX) | active not recruiting | Early Phase 1 | 28 | Andrew Hendifar, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT06418126 | Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer(TNBC-RT2023) | active not recruiting | N/A | 15 | Centre Paul StraussOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04762979 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | active not recruiting | Phase 2 | 44 | Marina N SharifiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07314255 | The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma(ZL2025) | active not recruiting | — | 60 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)(SKYSCRAPER-14) | active not recruiting | Phase 3 | 687 | Hoffmann-La RocheINDUSTRY | 27 | Dec 31, 2025 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | active not recruiting | Phase 3 | 687 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03673124 | Ribociclib and Letrozole Treatment in Ovarian Cancer | active not recruiting | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06822491 | Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response(PRODART) | active not recruiting | — | 28 | University of ZurichOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07298538 | Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer | active not recruiting | — | 800 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT04537312 | Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM) | active not recruiting | N/A | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06218511 | A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) | active not recruiting | Phase 1 | 10 | National Cancer Institute, NaplesOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02352883 | MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ | active not recruiting | N/A | 368 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT05030506 | A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | active not recruiting | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy(COSMIC-312) | active not recruiting | Phase 3 | 837 | ExelixisINDUSTRY | 34 | Dec 11, 2025 | clinicaltrials |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | active not recruiting | Phase 3 | 423 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07278102 | A Prospective Observational Study on Efficacy of TARE for Early Stage HCC(KURE-YTT-HCC) | active not recruiting | — | 200 | Seoul National University HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06105918 | Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer | active not recruiting | Phase 1 | 6 | Emory UniversityOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03511196 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | active not recruiting | Early Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04438681 | Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients(INSTIGO) | active not recruiting | — | 90 | Centre Jean PerrinOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05410951 | LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients(LobularCard) | active not recruiting | — | 800 | European Institute of OncologyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04002479 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer | active not recruiting | N/A | 37 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT04624477 | Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer | active not recruiting | — | 450 | University Health Network, TorontoOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT02921022 | Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | active not recruiting | N/A | 110 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02023463 | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | active not recruiting | Phase 1 | 25 | Thomas Jefferson UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06132087 | PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy | active not recruiting | N/A | 2 | University of Southern CaliforniaOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT04572633 | The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy(#HOPE4LIVER US) | active not recruiting | N/A | 47 | HistoSonics, Inc.INDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06328738 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | active not recruiting | Phase 1 | 275 | Enliven TherapeuticsINDUSTRY | 7 | Nov 19, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04902352 | The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer | active not recruiting | N/A | 102 | University Hospital Birmingham NHS Foundation TrustOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT01796145 | Fibroscan Study in HCC | active not recruiting | N/A | 207 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07230080 | Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer | active not recruiting | — | 17 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02827877 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | active not recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 6, 2026source: clinicaltrials